Organic compounds
US-2015197528-A1 · Jul 16, 2015 · US
Organic compounds
US9468637B2 · US · B2
| Field | Value |
|---|---|
| Publication number | US-9468637-B2 |
| Application number | US-201013319807-A |
| Country | US |
| Kind code | B2 |
| Filing date | May 13, 2010 |
| Priority date | May 13, 2009 |
| Publication date | Oct 18, 2016 |
| Grant date | Oct 18, 2016 |
How to read this patent
A practical reading order for non-experts. Skip the full description unless you need deep technical detail.
- Title
What the patent document calls the invention.
- Abstract
A short plain-language summary of the technical disclosure.
- Assignees and inventors
Who owns or filed the patent and who is credited as inventor.
- Key dates
Filing, priority, publication, and grant dates set the timeline.
- First independent claim
The legal scope of protection — read this for what is actually claimed.
- CPC / IPC classifications
Technology tags used to group this patent with similar filings.
- Citations and related patents
Prior art links and similar publications in this corpus.
Abstract
Official abstract text for this publication.
The present invention relates to a new use of phosphodiesterase 1 (PDE1) inhibitors for the treatment of psychosis, schizophrenia, schizoaffective disorder, schizophreniform disorder, psychotic disorder, delusional disorder, mania, or bipolar disorder.
First claim
Opening claim text (preview).
What is claimed is: 1. A method of treatment for psychosis, schizoaffective disorder, schizophreniform disorder, psychotic disorder, delusional disorder, mania or bipolar disorder comprising administering an effective amount of a PDE 1 inhibitor to a patient in need thereof wherein the PDE 1 inhibitor is: in free or salt form, including its enantiomers, diastereoisomers and racemates. 2. The method according to claim 1 , wherein the compound inhibits phosphodiesterase-mediated hydrolysis of cGMP or cAMP. 3. The method according to claim 1 , wherein the compound is a PDE1B inhibitor. 4. The method according to claim 1 , wherein the method further comprises administering a compound or compounds selected from typical and atypical antipsychotics to a patient in need thereof. 5. The method according to claim 1 , wherein the PDE1 inhibitor is in free or pharmaceutically acceptable salt form, in combination or association with a pharmaceutically acceptable diluent or carrier.
Assignees
Inventors
Classifications
Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00 · CPC title
Antipsychotics, i.e. neuroleptics; Drugs for mania or schizophrenia · CPC title
Anxiolytics · CPC title
- A61K31/495Primary
having six-membered rings with two {or more} nitrogen atoms as the only ring heteroatoms, e.g. piperazine {or tetrazines}(A61K31/48 takes precedence {; with three nitrogen atoms A61K31/53}) · CPC title
- A61K31/519Primary
ortho- or peri-condensed with heterocyclic rings · CPC title
Patent family
Related publications grouped by family.
External sources
Frequently asked questions
Answers are generated from the same data shown on this page.
- What does patent US9468637B2 cover?
- The present invention relates to a new use of phosphodiesterase 1 (PDE1) inhibitors for the treatment of psychosis, schizophrenia, schizoaffective disorder, schizophreniform disorder, psychotic disorder, delusional disorder, mania, or bipolar disorder.
- Who is the assignee on this patent?
- Fienberg Allen A, Wennogle Lawrence P, Mates Sharon, and 1 more
- What technology area does this patent fall under?
- Primary CPC classification A61K31/495. Mapped technology areas include Human Necessities.
- When was this patent published?
- Publication date Tue Oct 18 2016 00:00:00 GMT+0000 (Coordinated Universal Time) (B2). Legal status and post-grant events are not shown on this page.
- What related patents are in patentsdb?
- We list 3 related publications on this page (citations in our corpus or others sharing the same primary CPC).